GlaxoSmithKline PLCGSK:LSE

11.50 / 0.77%
Close in GBXToday's changeShares traded1 year changeBeta
Data delayed at least 15 minutes, as of Jan 23 2015 17:06 GMT.


On Friday, GlaxoSmithKline PLC (GSK:LSE) closed at 1,500, 15.70% above the 52 week low of 1,296.5 set on Oct 16, 2014.

52-week range
Oct 16 2014
Feb 21 2014
Markit short selling activity
Day high1,500.5
Day low1,481
Previous close1,488.5
Average volume9.16m
Shares outstanding4.86bn
Free float4.79bn
P/E (TTM)17.48
Market cap72.96bn GBP
EPS (TTM)0.8581 GBP
Annual div (TTM)80.00 GBX
Annual div yield (TTM)5.33%
Div ex-dateNov 06 2014
Div pay-dateJan 08 2015
Data delayed at least 15 minutes, as of Jan 23 2015 17:06 GMT.
Last IC View
The last IC recommendation on GlaxoSmithKline PLC shares was Buy at 1,356 on 16 Oct 2014
Read the full article

Comparative analysis

Past 90 days
1 week1 month6 months1 year5 years
GlaxoSmithKline PLC+4.82%+8.30%+5.41%-9.23%+18.11%
FTSE 100 Index+4.31%+3.56%+0.61%+0.88%+28.85%
GB/HEALTH CARE+2.56%+5.84%+4.88%+10.66%+34.37%
Data delayed at least 15 minutes, as of Jan 23 2015 17:06 GMT.
© Thomson Reuters Click for restrictions.

All markets data located on is subject to the FT Terms & Conditions.

All content on is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.

Any information that you receive via is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.

Markit Short Selling Activity © Markit. All rights reserved.
Although Markit has made every effort to ensure this data is correct, nevertheless no guarantee is given to the accuracy or completeness. Any opinions or estimates expressed herein are those of Markit on the date of preparation and are subject to change without notice; however no such opinions or estimates constitute legal, investment or other advice. You must therefore seek independent legal, investment or other appropriate advice from a suitably qualified and/or authorised and regulated advisor prior to making any legal, investment or other decision. This is intended for information purposes only and is not intended as an offer or recommendation to buy, sell or otherwise deal in securities.